Biblio
“Systematic lymphadenectomy in ovarian cancer at second-look surgery: a randomised clinical trial”, Br J Cancer, vol. 107, pp. 785-92, 2012.
, , “2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference.”, Int J Gynecol Cancer, vol. 21, no. 4, pp. 750-5, 2011.
, “Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial”, J Clin Oncol, vol. 29, pp. 3628-35, 2011.
, “Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010.”, Gynecol Oncol, vol. 121, no. 2, pp. 407-15, 2011.
, “Clinical trials and treatment of the elderly diagnosed with ovarian cancer.”, Int J Gynecol Cancer, vol. 21, no. 4, pp. 776-81, 2011.
, “Clinical trials in recurrent ovarian cancer.”, Int J Gynecol Cancer, vol. 21, no. 4, pp. 771-5, 2011.
, “Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy for the definitive treatment of cervix cancer.”, Int J Radiat Oncol Biol Phys, vol. 79, no. 2, pp. 348-55, 2011.
, “Correlation between CA-125 serum level and response by RECIST in a phase III recurrent ovarian cancer study.”, Gynecol Oncol, vol. 122, no. 2, pp. 350-5, 2011.
, “Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial.”, Gynecol Oncol, vol. 122, no. 2, p. 232, 2011.
, “Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)”, Int J Gynecol Cancer, vol. 21, pp. 419-23, 2011.
, “Development and validation of a nomogram to predict survival in CALYPSO and AGO-2.5 patients with platinum sensitive recurrent ovarian cancer. ”, Int J Gynecol Cancer , vol. 21, no. 12 Suppl 3, 2011.
, “Does severe anemia caused by dose-dense paclitaxel-Carboplatin combination therapy have an effect on the survival of patients with epithelial ovarian cancer? Retrospective analysis of the Japanese gynecologic oncology group 3016 trial.”, Int J Gynecol Cancer, vol. 21, no. 9, pp. 1585-91, 2011.
, “Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers”, Gynecol Oncol, vol. 122, pp. 233-7, 2011.
, “First-line therapy in ovarian cancer trials.”, Int J Gynecol Cancer, vol. 21, no. 4, pp. 756-62, 2011.
, “The global impact of the Gynecologic Cancer InterGroup in enhancing clinical trials in ovarian cancer.”, Int J Gynecol Cancer, vol. 21, no. 4, pp. 746-9, 2011.
, “The impact of dose intensity on the efficacy of gemcitabine plus carboplatin (GC) therapy for recurrent platinum-sensitive ovarian cancer (PSOC): A retrospective analysis of AGO-OVAR 2.5. ”, J Clin Oncol , vol. 29, no. suppl; abstr 5088, 2011.
, “Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer.”, Br J Cancer, vol. 105, no. 7, pp. 884-9, 2011.
, “Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study.”, Ann Oncol, vol. 22, no. 11, p. 2423, 2011.
, “Patient-reported outcomes: clinical trials in ovarian cancer.”, Int J Gynecol Cancer, vol. 21, no. 4, pp. 782-7, 2011.
, “A phase 3 trial of bevacizumab in ovarian cancer.”, N Engl J Med, vol. 365, no. 26, p. 2496, 2011.
, “a phase III trial of carboplatin and paclitaxel plus placebo versus carboplatin and paclitaxel plus concurrent bevacizumab followed by placebo, versus carboplatin and paclitaxel plus concurrent and extended bevacizumab, in women with newly diagnosied, pre”, N Engl J Med, vol. 365, p. 2483, 2011.
, “Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer.”, Br J Cancer, vol. 105, no. 8, pp. 1144-50, 2011.
, “Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO.”, Int J Gynecol Cancer, vol. 21, no. 2, p. 295, 2011.
, “Radiotherapy quality assurance of the Japanese Gynecologic Oncology Group study (JGOG1066): a cooperative phase II study of concurrent chemoradiotherapy for uterine cervical cancer”, Int J Clin Oncol, vol. 16, pp. 379-86, 2011.
,